Background
==========

Multiple myeloma (MM), the second most frequent hematologic malignancy after non-Hodgkin lymphoma, is characterized by the clonal expansion of malignant plasma cells in the bone marrow \[[@b1-medscimonit-24-6340],[@b2-medscimonit-24-6340]\]. Nearly 1--5 cases in 1000 persons are diagnosed with MM annually. MM represents about 20% of mortalities of all blood cancers \[[@b3-medscimonit-24-6340]\]. The availability novel agents including bortezomib, carfilzomib, thalidomide, lenalidomide, and pomalidomide has significantly improved the response rates and survival rates of patients with MM \[[@b4-medscimonit-24-6340]--[@b6-medscimonit-24-6340]\]. Although MM patients initially respond to treatment, they inevitably relapse due to acquired drug resistance \[[@b7-medscimonit-24-6340]\]. Although the 5-year survival rate for patients with MM is about 49%, the survival rate of patient with high-risk features is dismal \[[@b8-medscimonit-24-6340]\]. Therefore, accurate identification of this subset of patients is crucial to the diagnosis, treatment, and prognosis of patients with MM.

ARPC5, also known as actin related protein 2/3 complex subunit 5, encodes 1 of 7 subunits of the human Arp2/3 protein complex \[[@b9-medscimonit-24-6340],[@b10-medscimonit-24-6340]\]. Several studies demonstrated that ARPC5 was involved in tumor growth or metastasis of head and neck squamous cell carcinoma and lung squamous cell carcinoma, and cell differentiation \[[@b11-medscimonit-24-6340]--[@b12-medscimonit-24-6340]\]. Herein, we analyzed the relationship between ARPC5 expression and demographic and tumor characteristics of patients with MM.

Material and Methods
====================

Identification of MM microarray studies
---------------------------------------

MM microarray GSE24080 \[[@b13-medscimonit-24-6340],[@b14-medscimonit-24-6340]\] was contributed by the Myeloma Institute for Research and Therapy at the University of Arkansas for Medical Sciences. Pretreatment bone marrow plasma cells of 559 newly diagnosed MM patients in trial TT2 \[[@b15-medscimonit-24-6340],[@b16-medscimonit-24-6340]\] and TT3 \[[@b17-medscimonit-24-6340]\] were collected and gene expression profiling was conducted for these cases with Affymetrix Human Genome U133 Plus 2.0 gene chip. Demographic and tumor characteristics including age, gender, race, isotype, serum β-2 microglobulin, CRP, creatinine, lactate dehydrogenase, albumin, hemoglobin, rates of aspirate plasma cells, rates of bone marrow biopsy plasma cells, number of magnetic resonance imaging (MRI)-defined focal lesions, cytogenetic abnormalities, event-free survival and overall survival were well documented. GSE6477 \[18b19\] was contributed by Fonseca et al. A total number of 73 cases of newly diagnosed MM and 15 cases of normal donor were included. Gene expression profiling was conducted for these cases with Affymetrix Human Genome U133A gene chip. GSE31162 (*<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE31162>*) included gene expression data of 780 newly diagnosed MM and 258 relapsed MM. GSE19784 \[[@b20-medscimonit-24-6340]\], contributed by Broyl et al., was comprised of 328 previously untreated MM samples and annotated with Affymetrix Human Genome U133 Plus 2.0 Array. We used GSE14784 to perform gene set enrichment analysis (GSEA) \[[@b21-medscimonit-24-6340],[@b22-medscimonit-24-6340]\].

Data analysis
-------------

To evaluate the expression of ARPC5 in baseline MM, normal plasma, and relapsed MM, 2-sample *t*-test was conducted and relative expression of ARPC5 was presented as mean ± standard deviation. To determine the correlation between ARPC5 expression and demographic and tumor characteristics of patients with MM, patients in GSE24080 were divided into ARPC5 low expression group and ARPC5 high expression group based on the median of ARPC5 (the corresponding probe ID is 1555797_a\_at) expression in GSE24080, and then chi-square test and logistic regression analysis were performed. To investigate the prognostic value of ARPC5 in MM patients, Kaplan-Meier survival analysis and multivariable Cox proportional hazards analysis were conducted. If *P* values were less than 0.05, the differences were considered statistically significant. Finally, to characterize potentially relevant mechanisms for ARPC5 affected MM cells, GSEA was conducted.

MM sample collection, mononuclear separation, and quantitative PCR
------------------------------------------------------------------

Pretreatment bone marrow aspirates were obtained from10 newly diagnosed MM patients and 10 patients who were finally excluded based on the diagnosis of hematological malignances at Jingzhou Central Hospital. The collection of bone marrows was approved by the Ethics Committee of Jingzhou Central Hospital and the informed consents of the included participants were obtained. Bone marrow mononuclear cells were isolated by using the Ficoll-Hypaque density gradient protocol according to the manufacture's protocols. Total RNAs were isolated with TRIzol reagent (Invitrogen) according to manufacturer's instructions. After the synthesis of cDNA, quantitative PCR was performed using SYBR Premix ExTaq (TaKaRa, Japan) on an ABI7500 real-time PCR instrument (ABI Company, Oyster Bay, NY, USA) according to the manufacturer's instructions. Homo β-actin was treated as an internal control. The PCR detection was performed 3 times. Primers used in this study were as follows: ARPC5 forward: 5′-AAGTTCGTG GACGAGGAGG-3′, ARPC5 reverse 5′-GTAGGGCAGCGGTCATGTTTC-3′; β-actin forward: 5′-AGCGAGCATCCCCCAAAGTT-3′, reverse 5′-GGGCACGAAGGCTCATCATT-3′.

Results
=======

ARPC5 was significantly upregulated in baseline MM and relapsed MM
------------------------------------------------------------------

To explore whether ARPC5 was associated with carcinogenesis of MM, we analyzed the expression of ARPC5 in normal plasma cells, baseline MM cells, and relapsed MM cells using GSE6477 and GSE31162. As shown in [Figure 1](#f1-medscimonit-24-6340){ref-type="fig"}, the expression of ARPC5 was significantly increased in baseline MM cells (n=73) as compared to that in normal plasma cells (n=15) (2425±744.58 *vs.* 1935±850.61, *P*=0.0414, [Figure 1A](#f1-medscimonit-24-6340){ref-type="fig"}). Meanwhile, the expression of ARPC5 was significantly increased in relapsed MM cells (n=258) as compared to that in baseline MM cells (n=780) (1397±703.46 *vs.* 1096±552.62, *P*\<0.0001, [Figure 1B](#f1-medscimonit-24-6340){ref-type="fig"}).

Correlations between ARPC5 expression and demographic and tumor characteristics of patients with MM
---------------------------------------------------------------------------------------------------

Then, we analyzed the relationship between ARPC5 expression and clinical characteristics of MM patients. As shown in [Table 1](#t1-medscimonit-24-6340){ref-type="table"}, univariate analysis (chi-square test) suggested that pretreatment ARPC5 was associated with gender (P=0.014), serum β2-microglobulin (*P*\<0.0001), serum creatinine (*P*=0.019), serum lactate dehydrogenase (*P*=0.019), hemoglobin (*P*=0.001), rates of aspirate plasma cells (*P*=0.022), and number of magnetic resonance imaging (MRI)-defined focal lesions (*P*=0.049). Mutivariable analysis (logistic regression analysis) demonstrated that ARPC5 expression was significantly associated with β2-microglobin (*P*=0.047), serum lactate dehydrogenase (*P*=0.007), and rates of aspirate plasma cells (*P*=0.007). These results indicated that higher expression of ARPC5 expression was associated with poor tumor characteristics of patients with MM.

Higher expression of ARPC5 was associated with poor survivals of patients with MM
---------------------------------------------------------------------------------

We analyzed the prognostic significance of ARPC5 for MM patients in GSE24080. Patients in GSE20480 were divided into ARPC5 low expression group and ARPC5 high expression group based on the median of ARPC5 expression in GSE24080. Results of Kaplan-Meier survival analyses indicated that patients in the ARPC5 low expression group (n=280) were associated with more superior event-free survival (HR=0.718, 95% CI: 0.5577--0.9245, *P*=0.0102, [Figure 2A](#f2-medscimonit-24-6340){ref-type="fig"}) and overall survival (HR=0.6279, 95% CI: 0.4634--0.8508, *P*=0.0027, [Figure 2B](#f2-medscimonit-24-6340){ref-type="fig"}) compared with patients in the ARPC5 high expression group (n=279). Multivariable Cox proportional hazard analysis demonstrated that ARPC5 expression was an independent prognosis factor for event-free survival (*P*=0.006, HR=1.351, 95% CI: 1.092--1.672) and overall survival (*P*=0.020, HR=1.356, 95% CI: 1.05--1.75) of patients with MM ([Table 2](#t2-medscimonit-24-6340){ref-type="table"}).

ARPC5 was significantly increased in MM patients
------------------------------------------------

As stated earlier, we detected the expression of ARPC5 in bone marrow mononuclear cells of MM patients and normal donors who were excluded based on hematological malignance. These 10 MM patients included 6 males and 4 females, the median age was 63.5 years; 5 cases were IgG MM, 3 cases were IgA MM, 1 case was light chain MM, and 1 case was IgD MM ([Supplementary Table 1](#s1-medscimonit-24-6340){ref-type="supplementary-material"}). As shown in [Figure 3](#f3-medscimonit-24-6340){ref-type="fig"}, mRNA levels of ARPC5 were significantly increased in the bone marrow mononuclear cells of these 10 MM patients compared with that in patients with non-malignant bone marrow mononuclear cells (0.8160±0.136 *vs.* 0.4167±0.074, *P*\<0.0001).

Results of gene set enrichment analysis
---------------------------------------

In order to identify related molecular mechanisms involved in the function of ARPC5 in MM cells, GSEA analysis was conducted using another independent MM microarray study GSE19784 (MM samples in GSE19784 were divided into ARPC5 low expression group and ARPC5 high expression group according to the median of ARPC5 expression), as shown in [Figure 4](#f4-medscimonit-24-6340){ref-type="fig"}, the MM samples in ARPC5 mammalian target of rapamycin (mTOR)C1signaling were: nominal *P*\<0.0001, FDR=1.47%, enrichment score=0.57, normalized enrichment score=1.75. This result indicated that ARPC5 might promote the growth of MM cells through mTORC1 signaling.

Discussion
==========

Although significant improvements have been made regarding the diagnosis and treatment of patients with MM, the disease remains incurable due to acquired drug resistance \[[@b23-medscimonit-24-6340]\]. In the present study, we demonstrated that ARPC5 might be an independent risk factor of patients with MM.

The inclusion criteria for MM microarray studies resulted in a total number of 4 MM gene expression microarray studies that included more than 2055 participants who were selected for our analysis. GSE6477 included 73 samples of newly diagnosed MM and 15 samples of normal donor, thus, it was used to evaluate the expression of ARPC5 normal plasma cells and myeloma cells. GSE31162 included a great number of relapsed and newly diagnosed MM samples (780 relapsed MM and 258 newly diagnosed MM), thus, it was used to evaluate the expression ARPC5 in relapsed MM cells and newly diagnosed MM cells. Thanks to the large quantity of pretreatment MM samples and detailed clinical information of MM patients, GSE24080 was selected to analyze the relationship between ARPC5 expression and clinical features of patients with MM. The reason that GSE19784 was selected to perform GSEA analysis was attributed to the relative large number of MM samples in this dataset. In summary, the results of our study were based on the relative large number of participants in corresponding analyses.

Our results showed that ARPC5 was increased in baseline MM cells relative to normal plasma cells, and it was also increased in relapsed MM cells when compared with that in baseline MM cells, indicating that ARPC5 was associated with the carcinogenesis and progression of MM. The results of our correlation analysis, survival analysis, and clinical validation were in accordance with this conclusion. Results of GSEA indicated that ARPC5 might affect the proliferation of MM cells through mTORC1 signaling.

Moriya et al. suggested that the knockdown of microRNA-133a was associated with downregulation of APRC5, knockdown of ARPC5 inhibited the proliferation of lung squamous cell carcinoma and they concluded that ARPC5 might function as oncogenes in the development of lung squamous cell carcinoma \[[@b24-medscimonit-24-6340]\]. Liu et al. demonstrated that microRNA-141 inhibited the proliferation of prostate cancer stem cells by regulating ARPC5 as well as other Rho GTPase family members including (CDC42, CDC42EP3, RAC1) \[[@b11-medscimonit-24-6340]\]. Kinoshita et al. suggested that ARPC5 was a candidate target of miR-133a, and ARPC5 was significantly increased in head and neck squamous cell carcinoma compared with that in non-cancer tissues, and ARPC5 was also significantly increased in invasive cancer cells. Thus, they concluded that ARPC5 contributed to cancer cell migration and invasion in head and neck squamous cell carcinoma and this gene was directly regulated by miR-133a \[[@b12-medscimonit-24-6340]\]. In human osteosarcoma, Bernardini et al. demonstrated that the SI-83 induced dephosphorylation of ARPC5L, a subunit of the actin related Arp2/3 complex, and the decrease of other cytoskeleton proteins \[[@b25-medscimonit-24-6340]\]. These studies indicated that ARPC5 might play a role as oncogene in prostate cancer and head and neck squamous cell carcinoma.

Mammalian target of rapamycin (mTOR) represents a downstream serine/threonine kinase of the PI3K/Akt pathway that integrates signals from the tumor microenvironment to regulate multiple cellular processes, and TORC1was comprised of the mTOR catalytic subunit and 3 associated proteins, raptor, PRAS40, and mLST8/GβL \[[@b26-medscimonit-24-6340]\]. Maiso et al. demonstrated that downregulation TORC1 was associated with significant suppression of the growth of myeloma cells \[[@b26-medscimonit-24-6340]\]. Xiang et al. demonstrated that MK2206 combined with bufalin inhibited the proliferation and stimulated apoptosis of myeloma cells through the inhibition of the AKT/mTOR pathway \[[@b27-medscimonit-24-6340]\]. Yang et al. demonstrated that polydatin inhibited cell proliferation and induced apoptosis and autophagy of myeloma cells through the mTOR/p70s6k signaling pathway \[[@b28-medscimonit-24-6340]\]. These results indicated that the inhibition of mTOR signaling pathway was associated with cellular growth of MM cells. Our GSEA results indicated that APCR5 might inhibit the proliferation of MM cells through regulation of mTORC1 signaling pathway. Taking all these results into consideration, it could be speculated that ARPC5 might affect the growth of myeloma cells through regulation of mTOR signaling pathway.

Although several previous studies have evaluated the expression of some molecular using bone marrow mononuclear cells from MM patients and those conclusions have been widely accepted, our study has limitations. We analyzed the expression of ARPC5 in bone marrow mononuclear cells rather than CD138+ MM cells from MM patients; the expression of ARPC5 in bone marrow mononuclear cells might not fully reflect its expression in MM cells. Thus, the conclusions of clinical validation should be interpreted with caution, and we suggest future studies should detect ARPC5 expression in CD138^+^ MM cells.

Conclusions
===========

Our results indicated that ARPC5 was increased in myeloma cells, correlated with tumor characteristics of myeloma cells, therefore, ARPC5 could be treated as an independent risk factor of patients with MM.

Supplementary Table
===================

###### 

The clinical characteristics of ten MM patients.

  Patients ID   Gender   Age   M-protein type    ISS stage   Bone marrow biopsy plasma cells (%)   Relative expression of ARPC5
  ------------- -------- ----- ----------------- ----------- ------------------------------------- ------------------------------
  1             Female   68    IgA-Kap           3A          88                                    0.547445
  2             Male     70    IgA-Kap           3A          70                                    0.63868
  3             Male     64    IgA-Lam           2B          73                                    0.767532
  4             Female   59    IgD-Lam           3B          75                                    0.861735
  5             Male     51    IgG-Kap           3B          59                                    0.923884
  6             Female   60    IgG-Kap           3A          60                                    0.805834
  7             Female   63    IgG-Kap           3A          65                                    0.870867
  8             Male     64    IgG-Kap           3A          90                                    0.816188
  9             Male     48    IgG-Lam           3A          85                                    0.95939
  10            Male     66    Light Chain-Lam   3A          68                                    0.96821
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###### 

Correlations between ARPC5 expression and tumor characteristics of multiple myeloma patients.

  Characteristics                                                                                                                          ARPC5 expression   Univariate analysis   Multivariable analysis                                             
  ---------------------------------------------------------------------------------------------------------------------------------------- ------------------ --------------------- ------------------------ ---------------- ------- ---------------- -------
  Age (years)                                                                                                                                                                                                                                          
   ≤60                                                                                                                                     166                157                   0.214                    0.644            0.986   (0.966--1.007)   0.192
   \>60                                                                                                                                    113                123                                                                                      
  Gender                                                                                                                                                                                                                                               
   Male                                                                                                                                    154                183                   6.025                    0.014            0.779   (0.511--1.188)   0.246
   Female                                                                                                                                  125                97                                                                                       
  Race                                                                                                                                                                                                                                                 
   White                                                                                                                                   246                251                   0.307                    0.58             0.901   (0.471--1.723)   0.752
   Other                                                                                                                                   33                 29                                                                                       
  M protein[\*](#tfn2-medscimonit-24-6340){ref-type="table-fn"}                                                                                                                                                                                        
   IgG                                                                                                                                     141                172                   8.408                    0.078                                     
   IgA                                                                                                                                     77                 56                    0.389                    (0.34--4.631)    0.462                    
   FLC                                                                                                                                     47                 37                    0.785                    (0.066--9.29)    0.848                    
   IgD                                                                                                                                     2                  1                     0.533                    (0.044--6.451)   0.621                    
   NS                                                                                                                                      3                  5                     0.2                      (0.01--3.941)    0.29                     
  β2-microglobin (mg/mL)[\*](#tfn2-medscimonit-24-6340){ref-type="table-fn"}                                                                                                                                                                           
   \<3.5                                                                                                                                   138                181                   15.42                    P\<0.0001        1.091   (1.001--1.188)   0.047
   3.5--5.5                                                                                                                                67                 58                                                                                       
   ≥5.5                                                                                                                                    73                 41                                                                                       
  CRP (mg/L)[\*](#tfn2-medscimonit-24-6340){ref-type="table-fn"}                                                                                                                                                                                       
   \<5.8                                                                                                                                   151                173                   3.782                    0.052            0.998   (0.987--1.009)   0.704
   ≥5.8                                                                                                                                    127                104                                                                                      
  Creatinine (mg/dL)[\*](#tfn2-medscimonit-24-6340){ref-type="table-fn"}                                                                                                                                                                               
   \<1.2                                                                                                                                   174                200                   5.522                    0.019            0.93    (0.707--1.225)   0.608
   ≥1.2                                                                                                                                    104                78                                                                                       
  LDH (U/L)                                                                                                                                                                                                                                            
   \<170                                                                                                                                   150                178                   5.544                    0.019            1.005   (1.001--1.009)   0.007
   ≥170                                                                                                                                    129                102                                                                                      
  ALB (g/dL)                                                                                                                                                                                                                                           
   \<3.5                                                                                                                                   46                 31                    3.451                    0.063            0.759   (0.508--1.136)   0.18
   ≥3.5                                                                                                                                    233                249                                                                                      
  HGB (g/dL)                                                                                                                                                                                                                                           
   \<11                                                                                                                                    142                105                   10.169                   0.001            0.916   (0.798--1.050)   0.207
   ≥11                                                                                                                                     137                175                                                                                      
  ASPC[\*](#tfn2-medscimonit-24-6340){ref-type="table-fn"} (%)                                                                                                                                                                                         
   \<40                                                                                                                                    139                116                   5.244                    0.022            0.983   (0.972--0.996)   0.007
   ≥40                                                                                                                                     123                153                                                                                      
  BMPC (%)[\*](#tfn2-medscimonit-24-6340){ref-type="table-fn"}                                                                                                                                                                                         
   \<50                                                                                                                                    143                131                   1.554                    0.213            0.999   (0.988--1.01)    0.864
   ≥50                                                                                                                                     126                143                                                                                      
  MRI (Magnetic resonance imaging (MRI)-defined focal lesions (skull, spine, pelvis)[\*](#tfn2-medscimonit-24-6340){ref-type="table-fn"}                                                                                                               
   Yes                                                                                                                                     200                180                   3.87                     0.049            1.01    (0.999--1.028)   0.078
   No                                                                                                                                      61                 81                                                                                       
  Cytogenetic abnormalities                                                                                                                                                                                                                            
   Yes                                                                                                                                     104                103                   0.014                    0.904            0.98    (0.64--1.502)    0.927
  No                                                                                                                                       175                177                                                                                      

CRP -- C-reactive protein; LDH -- lactate dehydrogenase; ALB -- albumin; HGB -- hemoglobin; ASPC -- aspirate plasma cells; BMPC -- bone marrow biopsy plasma cells;

indicates that the corresponding data for that clinical phenotype has some missing values.

###### 

Multivariable Cox proportional hazard analysis on Overall survival and event free survival of patients with multiple myeloma.

  Characteristics   Overall survival   Event free survival                                              
  ----------------- ------------------ --------------------- ----------------------- ---------- ------- ----------------
  ARPC5             0.02               1.356                 (1.05--1.75)            0.006      1.351   (1.092--1.672)
  Age               0.271              1.01                  (0.992--1.028)          0.633      0.996   (0.982--1.011)
  Sex               0.515              1.125                 (0.79--1.602)           0.274      1.176   (0.879--1.572)
  Type              0.884                                                            0.023              
   Type (1)         0.889              1.153                 (0.157--8.481)          0.143      0.415   (0.128--1.348)
   Type (2)         0.995              1.006                 (0.136--7.45)           0.168      0.435   (0.133--1.42)
   Type (3)         0.887              0.863                 (0.113--6.582)          0.019      0.231   (0.068--0.789)
   Type (4)         0.955              \<0.0001              (\<0.0001--\<0.00001)   0.034      0.085   (0.009--0.835)
  B2M               \<0.0001           1.098                 (1.056--1.142)          \<0.0001   1.088   (1.05--1.127)
  CRP               0.489              0.997                 (0.988--1.006)          0.489      0.997   (0.99--1.005)
  Creatinine        0.262              0.917                 (0.788--1.067)          0.604      0.965   (0.845--1.103)
  LHD               \<0.0001           1.005                 (1.003--1.007)          0          1.004   (1.002--1.006)
  ALB               0.06               0.747                 (0.552--1.012)          0.407      0.900   (0.701--1.155)
  HGB               0.892              1.008                 (0.904--1.123)          0.38       0.959   (0.873--1.053)
  ASPC              0.797              0.999                 (0.989--1.009)          0.413      0.997   (0.988--1.005)
  BMPS              0.875              1.001                 (0.991--1.01)           0.711      1.001   (0.994--1.009)
  MRI               0.076              1.010                 (0.999--1.02)           0.279      1.005   (0.996--1.015)
  CA                0.001              0.549                 (0.388--0.777)          0.003      0.645   (0.483--0.863)
  RACE              0.846              0.948                 (0.554--1.623)          0.116      1.482   (0.908--2.420)
  Treatment         0.32               1.244                 (0.809--1.913)          0.004      1.691   (1.178--2.428)

CRP -- C-reactive protein; LDH -- lactate dehydrogenase; ALB -- albumin; HGB -- haemoglobin; ASPC -- aspirate plasma cells; BSPC -- bone marrow biopsy plasma cells; CA -- vytogenetic abnormalities.
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